Martek Biosciences Corp. (NASDAQ:MATK)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $31.49 |
| Daily Range | $31.48 - $31.54 |
| 52-Week Range | $17.95 - $32.75 |
| Market Cap | $1.06B |
| P/E Ratio | 38.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 0 |
| Average Daily Volume | 0 |
MATK
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MATK Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
- Idenix Pharmaceuticals Shares Dropped: What You Need to Know – The Motley Fool
- What's Going on With These Biotech Stocks? – The Motley Fool
- Gilead Sciences Shares Surged: What You Need to Know – The Motley Fool
- Has Elan Become the Perfect Stock? – The Motley Fool
- Whoa! What Just Happened to My Stock? – The Motley Fool
- The Disadvantage of a Successful Pipeline – The Motley Fool
- Has Amgen Become the Perfect Stock? – The Motley Fool
- New CEO = Dendreon Takeover Target? – The Motley Fool
- Maximum Market: $2.9 Billion, For Now – The Motley Fool
- Side Effect of Low Side Effects: 20% Stock Gain – The Motley Fool
- FDA Approval Isn't Enough – The Motley Fool
- Which Big Biotech Is the Best Bet? – The Motley Fool
RSS Headlines
Fool UK
